Doctors condemn NICE's guidance on leukaemia drug

BMJ 2002; 324 doi: (Published 08 June 2002) Cite this as: BMJ 2002;324:1352
  1. Susan Mayor
  1. London

    Leukaemia specialists in the United Kingdom are actively campaigning to overturn draft guidance issued by the National Institute for Clinical Excellence (NICE) that the signal transduction inhibitor imatinib (Glivec) should be used only in NHS patients with advanced chronic myeloid leukaemia.

    The NICE appraisal consultation document recommends imatinib for the treatment of patients with accelerated phase chronic myeloid leukaemia (CML). However, it did not recommend its use for …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription